| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate |
2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008526686-A |
| titleOfInvention |
Formulation for immunotherapy having neutralizing ability of interleukin-2 |
| abstract |
The present invention relates to a pharmaceutical preparation that can be used in connection with cancer and blocks the binding of interleukin-2 (IL-2) to the interleukin-2 receptor. More specifically, the present invention binds IL-2 to the IL-2 receptor by binding IL-2 to the Neisseria meningitidis transport protein P64k in the adjuvant Montanide ISA 51. It relates to therapeutic formulations capable of enhancing the immunogenicity of IL-2 for the induction of blocking autoantibodies. The invention also relates to a method effective for the treatment of tumors including breast cancer. The present invention further provides therapeutic treatment of IL-2 based vaccines with other cancer vaccines based on tumor specific antigens or tumor growth factors, and radiation or chemotherapeutic agents traditionally used in oncology practice. Related to various combinations. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017519970-A |
| priorityDate |
2004-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |